Clinical trials: in Chile
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease…
- Trial name
- PHOENYCS FLY (NCT06617325)
- Testing
- DZP
- Where
- 245 sites in United States, Argentina and 21 more
- Volunteers
- 450 people
- Sponsor
- UCB Biopharma SRL
Carcinoma
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in participants with epidermal growth factor receptor mutation positive (EGFRm+) and mesenchymal epithelial transition…
- Trial name
- SAVANNAH (NCT03778229)
- Testing
- Osimertinib, Savolitinib
- Where
- 90 sites in United States, Brazil and 11 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage…
- Trial name
- KANDLELIT-013 (NCT07431827)
- Testing
- Calderasib, MK-3475A
- Where
- 120 sites in Argentina, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Cancer
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy…
- Trial name
- CheckMate901 (NCT03036098)
- Testing
- Nivolumab, Ipilimumab, Gemcitabine
- Where
- 174 sites in United States, Argentina and 28 more
- Volunteers
- 1,314 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm Malignant
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation.
- Trial name
- KANDLELIT-014 (NCT07209111)
- Testing
- Calderasib, Cetuximab
- Where
- 72 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC).
- Trial name
- NCT06712316
- Testing
- Pumitamig, Pembrolizumab, Carboplatin
- Where
- 366 sites in United States, Argentina and 20 more
- Volunteers
- 1,580 people
- Sponsor
- BioNTech SE
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 103 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell…
- Trial name
- NCT06525220
- Testing
- Petosemtamab, Pembrolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 699 people
- Sponsor
- Genmab
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.
- Trial name
- NCT06430801
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 499 sites in United States, Australia and 45 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Generalized Tonic-Clonic Seizures
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic…
- Trial name
- X-ACKT (NCT05667142)
- Testing
- XEN1101
- Where
- 141 sites in United States, Argentina and 18 more
- Volunteers
- 160 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee…
- Trial name
- HORIZON 1 (NCT05170204)
- Testing
- Alectinib, Entrectinib, Durvalumab
- Where
- 45 sites in United States, Australia and 17 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
- Trial name
- NCT06395103
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Australia and 21 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Lupus Erythematosus, Systemic
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms.
- Trial name
- OPUS-2 (NCT05672576)
- Testing
- Cenerimod
- Where
- 147 sites in United States, Chile and 16 more
- Volunteers
- 451 people
- Sponsor
- Viatris Innovation GmbH
Pulmonary Fibrosis
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for…
- Trial name
- NCT07441408
- Testing
- BMS-986278
- Where
- 275 sites in United States, Argentina and 25 more
- Volunteers
- 2,380 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis (UC)
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B).
- Trial name
- NCT06619990
- Testing
- XmAb942
- Where
- 114 sites in United States, Argentina and 17 more
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Metastatic Castration-Resistant Prostate Cancer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
- Trial name
- NCT06629779
- Testing
- PF-06821497, Enzalutamide
- Where
- 231 sites in United States, Argentina and 25 more
- Volunteers
- 900 people
- Sponsor
- Pfizer
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Neoplasm
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
- Trial name
- NCT07247110
- Testing
- MK-4716, Pembrolizumab, Cetuximab
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer, Prostatic Neoplasms
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC.
- Trial name
- NCT06925737
- Testing
- Ifinatamab deruxtecan, Docetaxel, Prednisone
- Where
- 303 sites in United States, Argentina and 33 more
- Volunteers
- 1,440 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.